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SUMMARY
Following  the  observation  from  our  experience  with  the 
Northern Ireland Motor Neurone Disease (MND) register 
that excessive delays appeared to exist in the diagnosis of 
patients with MND, we performed a population-based study 
of the length and factors involved in the diagnostic process. In 
73 patients we found that the median time to diagnosis from 
symptom onset was 15.6 months, being shorter in bulbar onset 
patients and longer in females or those presenting with non-
specific gait disturbance. We divided this interval into three 
time periods – symptom onset to first medical contact, first 
medical contact to neurology referral and neurology referral 
to  diagnosis. The  time  period  from  first  medical  contact 
to neurology referral was the longest of the three periods 
studied indicating that appropriate timely referral of patients 
to  neurologists  was  responsible  for  the  greatest  delay  in 
making a diagnosis of MND. We propose that improving the 
accessibility of neurological services could potentially reduce 
the time to diagnosis by at least three months. 
INTRODUCTION
From our experience in setting up the Northern Ireland Motor 
Neurone Disease (MND) register, in August 2004, we felt 
that excessive delay existed in the diagnosis of patients with 
MND. Timeliness is an essential component of high quality 
health  care1  particularly  in  such  a  devastating  diagnosis 
as MND. Earlier diagnosis in patients could mean earlier 
commencement on riluzole, the only licensed treatment for 
MND, as well as a greater opportunity to become enrolled 
in  clinical  drug  trials.  It  is  also  likely  that  significant 
psychological stress accompanies the wait for a diagnosis. 
A  study  by  Johnston  et  al2  reported  that  the  majority  of 
MND patients described positive aspects of being given their 
diagnosis, particularly because they now had a ‘label’ for their 
condition. Furthermore, earlier diagnosis allows patients more 
time to make personal and financial adjustments and make 
plans for the future, including the modification of their home 
to cope with impending disability.
The  latency  from  symptom  onset  to  diagnosis  in  MND 
documented in the literature has shown little improvement or 
change over the last 40 years and figures range from 10.6-17.5 
months3-13. Two recent studies4,10 looked at the factors leading 
to such delay. The first study10 ascertained patients solely 
via the Motor Neurone Disease Association (MNDA) and 
collected data directly from patients. Using this method one 
cannot assess the validity of the diagnoses and in addition it 
is very unlikely that patients will be able to recall accurately 
the details of their diagnostic process. Although the second 
study4 used data from structured case reports completed by 
consultant neurologists we feel the most robust and accurate 
method to examine the diagnostic process in MND would 
be to review GP (General Practitioner) records. In the vast 
majority of patients, the GP would be the first point of contact 
for patients and GP records would contain all correspondence 
between various hospital specialists. In addition, our study has 
the added advantage of being population-based due to a well 
maintained register of MND patients in Northern Ireland.
Using the MNDA‘s ‘Standards of Care’ document (Table 
1), we performed a population-based case note review to 
study the length of the diagnostic process of MND and the 
contributing factors using both primary care and hospital 
records. 
METHODS
We  used  the  MNDA’s  ‘Standards  of  Care’  for  our  study. 
Ethical committee approval was obtained for the setting up of 
an MND register. We identified all patients from the Northern 
Ireland MND register prevalent on 1st January 2006. All were 
diagnosed by a consultant neurologist and fulfilled the original 
Ta b l e  I 
Standards of care used for the study
Standards of care to achieve quality of life for people 
affected by Motor Neurone Disease
Before diagnosis:
Speed in acquiring the correct diagnosis through
(a) Early recognition of symptoms which might suggest 
the diagnosis
(b) Earliest possible assessment by neurologist© The Ulster Medical Society, 2008.
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El Escorial criteria, and gave written informed consent for 
their medical notes to be examined. All GP and hospital notes 
were examined (by CD and AD). Data was collected using a 
structured form that focused on the time periods from initial 
medical contact to diagnosis as well as the nature or specialty 
of the physicians involved
We  used  median  instead  of  mean  values  in  calculating 
time  periods  because  the  prevalent  population  (Table  2) 
included some long living MND patients who had presented 
insidiously. 
RESULTS
There were 83 patients with MND prevalent on the register on 
the 1st January 2006 and we were able to include 73 patients 
providing  88%  ascertainment.  We  were  unable  to  obtain 
consent from nine patients while another had no primary care 
records available due to their diagnosis being made outside 
Northern Ireland. These cases were excluded. Ascertainment 
of cases was 99.5% based on unpublished results from a 
capture-recapture analysis performed on a prevalence study 
on 30th June 2005. Capture-recapture analysis is a method of 
counting the total number of cases within a population from 
two  or  more  overlapping  incomplete  but  distinct  sources 
which allows estimation of the number of unobserved cases 
and can determine the completeness of ascertainment14. We 
used multiple sources to ascertain cases and minimise bias.
The median time to diagnosis from symptom onset (TTD) 
was 15.6 months and the time period from first physician 
contact to neurology referral was proportionately the longest 
(figure 1). There was no correlation between TTD and age. 
TTD was longer in females, 20.9 months, compared to males, 
13.9 months, and this was due largely to the time period from 
neurology referral to diagnosis (2.7 months in males and 5.2 
in females).   
The impact of the physicians involved 
The GP was the first physician contacted in 67/73 or 92% of 
cases. Three patients attended the Accident and Emergency 
department when presenting first and for two it was unknown. 
One  patient  who  had  frontotemporal  dementia  associated 
MND presented to a psychiatrist with concerns from her 
family that she had depression. The first specialist seen was 
the neurologist in 28/73 (37% ) cases (figure 2). Appropriate 
onward referral to neurologists from the first specialist seen 
ranged from 14 to 57%. Referral was lowest in those seen 
by ENT surgeons (7 patients, figure 3). The highest level of 
appropriate onward referral was by surgeons (orthopaedic 
and neurosurgeons) at 57%. One might have expected that 
physicians would have referred more than 50% of the patients 
they saw onto a neurologist.
The  impact  of  site  of  onset  of  disease  and  presenting 
symptoms
TTD was shorter in bulbar onset (13.5 months) as compared 
to limb onset disease (17 months) particularly the time period 
from  neurology  referral  to  diagnosis  which  was  shorter 
in  bulbar  onset  (2.2  months)  as  compared  to  limb  onset 
disease (4.6 months). The TTD in bulbar onset disease was 
24.7 months for those initially referred to an ENT surgeon 
(7/19), and only 4.9 months for those referred directly to a 
neurologist (3/19) and 12.2 months for the remaining 9/19 
patients referred to other specialists.
Although responsible for only 8% of patients, non-specific 
gait disturbance was associated with the longest TTD due to a 
delay within all time periods (Table III). This group presented 
with gait disturbance without evidence of weakness or foot 
drop, and tended to have upper motor neurone predominant 
MND. Whilst MND is believed to be a painless condition 
many  patients  do  complain  of  pain  not  associated  with 
identifiable trauma as was the case in four of our patient 
group.  
Fig 2. 1st Specialist seen on referral from 1st medical contact
Fig 3.  Appropriate onward referral from non-neurologists
Ta b l e  II. 
Demographics & Clinical details 
Male : Female ratio 1.4 : 1
Site of disease onset Bulbar (n=19)
Limb (n=52)
Cognitive (n=2)
Mean age at symptom onset 60 years (SD 13.7)
Mean age at diagnosis 61.8 years (SD13.6)
Fig 1. Median time periods (months)© The Ulster Medical Society, 2008.
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Misdiagnosis
The  final  diagnosis  of  MND  was  given  to  the  patient 
by  a  neurologist  in  69/73  (95%)  of  cases  and  a  general 
physician in 4/73 (5%) of cases although all patients had 
their diagnosis confirmed by a neurologist as is appropriate. 
Initial incorrect diagnoses were made in 20/73 cases (27%). 
These falsely negative diagnoses were made by neurologists 
in 7 of the 69 patients, by GPs in 3 before onward referral 
and by non-neurology specialists in 10 of the 45 cases seen 
before being referred onto neurologists. Table IV lists the 
range of diagnoses. TTD was longer in the group who were 
misdiagnosed (26.3 months) when compared to those who 
were not (13.8 months). No correlation was found between 
misdiagnosis and age.
DISCUSSION 
The TTD  in  our  study  was  15.6  months  and  the  longest 
median  time  period  responsible  for  this  latency  was  that 
time spent with a physician before a neurology referral was 
made (4.8 months). Only 37% of patients were referred to 
a neurologist as the first specialist and of those referred to 
non-neurologists only 40% were appropriately referred on 
to a neurologist. If 80% of patients were to be referred to a 
neurologist as the first specialist then the median TTD could 
be reduced by just over 3 months.
When one considers that the current survival of MND in 
Ireland is 16.4 months from diagnosis until death15, a wait 
of 15.6 months from symptom onset to diagnosis appears 
excessive. The MNDA’s standards of care before diagnosis 
(table I), detail that speed in achieving a diagnosis should be 
attained through ‘early recognition of symptoms’ and ‘earliest 
possible assessment by a neurologist’. These two key areas 
appear to be responsible for the greatest delay in this patient 
group.  Our  results  indicate  that  GPs  and  non-neurology 
specialists are not referring patients to neurologists quickly 
enough, in particular ENT surgeons. This may be due to a 
combination of poor recognition of neurological signs and 
symptoms however it is more likely that GPs are disillusioned 
with the waiting times for neurology outpatient appointments 
(6 – 12 months at the time of this study) and simply try to 
find other specialists that might be able to help. Nonetheless 
presentations  such  as  non-painful  gait  disturbance, 
progressive bulbar dysfunction and fasciculations, when they 
are associated with wasting or weakness, always necessitate 
neurological assessment. ENT surgeons need also to be aware 
that progressive bulbar dysfunction not due to a structural 
cause requires urgent referral to a neurologist. 
What can one learn from this study and what can be done to 
help? The time period from presentation to neurology referral 
is the best place to target improvements - GPs need to refer 
appropriate patients directly to neurologists. We know that 
new neurological outpatients are more efficiently managed 
by  neurologists  than  general  physicians16.  Furthermore 
Ta b l e  III.
Median time periods dependent on nature of predominant 1st symptom
Median time (months)
Time periods Weakness
(n=36, 50%)
Bulbar
(n=19, 26%)
Cognitive
(n=2, 3%)
Non-specific gait 
disturbance
(n=6, 8%)
Fasciculation /
Cramps
(n=6, 8%)
Pain
(n=4, 5%)
Symptom onset to 1st 
physician contact 2.6 2.0 5.8 11.0 9.6 0.1
1st physician contact to 
neurology referral 4.2 4.8 5.4 9.6 2.4 10.7
Neurology referral to 
diagnosis 4.8 2.2 2.2 13.3 2.7 0.8
Symptom onset to 
diagnosis (TDD) 15.5 13.5 13.1 33.6 15.6 13.0
Ta b l e  IV . 
Falsely negative diagnoses
Diagnoses
Cervical Spondylosis
Nothing
Neuropathy
Lumbar disc prolapse
Capsulitis of shoulder joint
Myelopathy
Multiple sclerosis
Parkinson’s Disease
Stroke
Carpal Tunnel Syndrome
Vascular pseudobulbar palsy
Osteoarthritis
Rhinitis
Depression© The Ulster Medical Society, 2008.
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the  results  from  this  study  indicate  that  neurologists  are 
successfully  prioritising  referrals  on  patients  with  MND, 
with a median waiting time of 1.3 months from neurology 
referral to appointment with the neurologist, and GPs should 
be  encouraged  by  this.  Ultimately  making  neurologists 
more accessible would encourage GPs to make appropriate 
referrals for patients with neurological symptoms or signs. 
One approach that might help would be the introduction of 
an email triage system as examined by Patterson et al17. This 
allows a neurologist to deal with appropriate GP referrals 
using email and shorten the time for a clinic appointment. 
The recent establishment of the Northern Ireland MND Care 
Centre may also help as the care centre coordinator can accept 
referrals  from  non-neurologists  concerning  patients  with 
suspected MND and ‘fast track’ them through the system.  
The strengths of our study are that this is a population-based 
study with a high level of ascertainment and both GP and 
hospital records were used to allow as accurate information to 
be collected as possible. This robust methodology is lacking 
from previous studies. The weakness of this study is that it is 
from a single region and does not necessarily reflect practice 
in the rest of the UK and beyond. It is likely that similar trends 
exist within the rest of the UK. 
Our TTD was consistent with that documented in the literature 
of  10.6-17.5  months3-13 although  our  misdiagnosis  rate  of 
27% was at the lower end of reported figures 27-61%4,10,18,19. 
In a survey involving Germany, Spain, Italy, USA, Brazil 
and Argentina4, 63% of patients were referred directly to a 
Neurologist from the GP. In a study performed in England 
and Wales the reported rate was 47%10. Although these rates 
seem  much  better  than  our  37%,  these  studies  were  not 
population based. If the reported rates in these studies were 
indeed representative of the population from which they were 
drawn it may be in part due to the increased accessibility 
of  neurologists  in  some  European  countries  compared  to 
Northern Ireland. Both studies noted that the main delay 
appeared  to  be  in  the  time  period  from  presentation  to 
neurology referral.
With  improvements  in  the  accessibility  of  neurological 
services we feel that the median time period from presentation 
to neurology referral of 4.8 months could be reduced by three 
months or more. As this represents approximately 10% of the 
average survival of MND patients from symptom onset, it 
would be an effort worth making. 
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